Ryan Livingston

Although shown to have no connection to autism in multiple studies, the mercury-based agent will no longer be included in multidose influenza shots.

Announced by Aldeyra Therapeutics, Inc. on July 17, the FDA also assigned a PDUFA target action date of December 16, 2025.

Already approved by the FDA based on data from the first half of the PaTHway trial, 3-year extended results have indicated lasting efficacy.

The previously approved technology has already accomplished over 10,000 procedures for patients with various heart diseases, primarily including atrial fibrillation.

BaxHTN trial results showed baxdrostat led to a significant reduction of systolic blood pressure compared to placebo, with a favorable safety profile.

The FDA also announced an updated PDUFA date of December 13, 2025 for the self-administered nasal spray.

Capricor Therapeutics intends to resubmit a BLA for the potential first-in-class treatment with topline data from the ongoing HOPE-3 trial in Q3 2025.

Based on reduced FOXP3+ expression in patients, investigators have drawn a strong correlation between MetS due to psoriasis and immune dysregulation.

Gastrointestinal disorders, atopic conditions, and other diseases may have similar or shared pathogenetic mechanisms with AA, based on recent research.

Based on 8 major questions and consisting of 9 formal recommendations, the SCAI’s guidelines aim to advise clinicians on what treatments to use when.

According to recent research, more patients surviving heart diseases correlates directly to higher mortality rates for ischemic and chronic heart conditions.

Our recap of the first half of 2025 highlights 5 regulatory updates, 5 trial announcements, and 3 top perspectives in hematology.

Our recap of the first half of 2025 highlights 5 regulatory updates, 5 trial announcements, and 3 top perspectives in eyecare.

The results of the ZENITH trial have encouraged the expansion of sotatercept’s label to patients with prior background therapy.

A relatively quiet quarter for hematology, punctuated by both successes and failures in clinical trials and a handful of Orphan Drug and Fast Track designations.

Our Q2 2025 recap for ophthalmology highlights 5 regulatory updates, 5 important trial announcements, and top perspectives in eyecare.

The FDA distributed several designations and many trials successfully met their endpoints during an eventful June for hematology.

June was characterized by HCPLive’s coverage of the AOA 2025 Conference in Minneapolis and a host of cross-specialty disease indicators and drug uses.

A worldwide increase in both near-work and screen usage has led to a spike in myopia rates; this study associates this with near exophoria caused by close reading.

A recent post hoc analysis of 2 pivotal phase 3 trials has determined the efficacy of acoltremon .003% in reducing ocular surface damage in dry eye disease.

Based on recent data, artificial intelligence can improve patients’ awareness of their condition, as well as confidence in, and satisfaction with, their care.

Research has indicated a substantial increase in axial length, a contributing factor of myopia, in young adults who report regular mobile device usage.

Despite its availability as an over-the-counter medication, BTOS is frequently prescribed by clinicians for the treatment of ocular redness due to minor eye irritations.

This interim report of an ongoing study has indicated an overall positive impression of the INFUSE for Astigmatism contact lens among a 100-patient population.

A survey study has indicated a substantially positive perspective on UMFfA contact lenses, including reports on well-maintained vision, comfort, and ease of fitting.

Lifitegrast 5% led to improvements in OSDI, MMP-9, tear osmolarity, and a variety of other biomarkers and clinical signs of DED.

A recent cross-sectional analysis has estimated the size of the American population with both MASLD and T2DM eligible for treatment.

The Phase 3 HYPERION trial achieved its primary endpoint of lower time to clinical worsening, measured by a variety of related factors.

Parent company Novo Nordisk has announced intentions to submit the treatment for approval later in 2025.

Data from the Phase 1/2 BEACON trial indicate the efficacy and safety of this investigative 1-time therapy, particularly in decreasing blood cell sickling.